WO2006076003A3 - Vaccinia virus strains - Google Patents

Vaccinia virus strains Download PDF

Info

Publication number
WO2006076003A3
WO2006076003A3 PCT/US2005/012947 US2005012947W WO2006076003A3 WO 2006076003 A3 WO2006076003 A3 WO 2006076003A3 US 2005012947 W US2005012947 W US 2005012947W WO 2006076003 A3 WO2006076003 A3 WO 2006076003A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccinia virus
virus strains
methods
vaccines
patients
Prior art date
Application number
PCT/US2005/012947
Other languages
French (fr)
Other versions
WO2006076003A2 (en
Inventor
Richard A Weltzin
Thomas P Monath
Original Assignee
Acambis Inc
Richard A Weltzin
Thomas P Monath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc, Richard A Weltzin, Thomas P Monath filed Critical Acambis Inc
Publication of WO2006076003A2 publication Critical patent/WO2006076003A2/en
Publication of WO2006076003A3 publication Critical patent/WO2006076003A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation

Abstract

The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.
PCT/US2005/012947 2004-04-16 2005-04-14 Vaccinia virus strains WO2006076003A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/826,680 2004-04-16
US10/826,680 US7645456B2 (en) 2001-04-23 2004-04-16 Vaccinia virus strains

Publications (2)

Publication Number Publication Date
WO2006076003A2 WO2006076003A2 (en) 2006-07-20
WO2006076003A3 true WO2006076003A3 (en) 2007-06-28

Family

ID=36678025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012947 WO2006076003A2 (en) 2004-04-16 2005-04-14 Vaccinia virus strains

Country Status (2)

Country Link
US (2) US7645456B2 (en)
WO (1) WO2006076003A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
WO2004067032A2 (en) 2003-01-24 2004-08-12 University Of Massachusetts Medical Center Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US7807180B2 (en) 2007-08-21 2010-10-05 University Of Massachusetts Poxvirus methods and compositions
WO2011056771A2 (en) * 2009-11-03 2011-05-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Centers For Disease Control And Prevention Diagnostic assays for chordopoxviruses
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
JP2015524670A (en) * 2012-08-16 2015-08-27 エヌブイエス テクノロジーズ，インコーポレイティド Assay methods and systems
AU2012391162A1 (en) * 2012-09-28 2015-04-09 Probiogen Ag Novel MVA virus and uses thereof
JP7072521B2 (en) 2016-04-22 2022-05-20 バクシネックス インコーポレーティッド Presentation of Integral Membrane Proteins on Poxvirus Extracellular Envelope Billions
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2020011754A1 (en) * 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CN113347993A (en) * 2018-10-22 2021-09-03 艾赛澳克莱克斯疗法有限责任公司 Mutant vaccinia virus and uses thereof
EP3876951A1 (en) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
WO2020136232A1 (en) * 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
CN114867738A (en) 2019-10-02 2022-08-05 拜耳诺克斯有限公司 Tumor targeting protein or fragment thereof, antibody binding thereto, and use thereof
US11110165B2 (en) 2019-10-10 2021-09-07 Ricardo Rosales Ledezma Therapeutic vaccine for the treatment of papillomavirus lesions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315914A (en) 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
JPS60202827A (en) 1984-03-28 1985-10-14 Chibaken Attenuated variola vaccine strain
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
US6723325B1 (en) * 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOEBEL S.J. ET AL.: "The complete DNA sequence of vaccinia virus", ILLINOIS MEDICAL JOURNAL, vol. 179, no. 1, 1990, pages 247 - 266, XP000253545 *
LAZOWSKIES P.F.: "COMPARATIVE RESULTS OF SMALLPOX REVACCINATION USING REGULAR AND DRY SMALLPOX VACCINE (DRYVAX)", MED. J., vol. 125, February 1964 (1964-02-01), pages 140 - 141, XP008082546 *

Also Published As

Publication number Publication date
US7645456B2 (en) 2010-01-12
WO2006076003A2 (en) 2006-07-20
US20090324548A1 (en) 2009-12-31
US20090169512A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
WO2006076003A3 (en) Vaccinia virus strains
WO2008100292A3 (en) Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2006015035A8 (en) Useful compounds for hpv infection
WO2007030810A3 (en) Multiparameter whole blood monitor and method
WO2005082020A8 (en) Flavivirus vaccines
WO2006044857A3 (en) Vaccines against japanese encephalitis virus and west nile virus
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2006020773A3 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
MX2009011002A (en) Ischemia/reperfusion protection compositions and methods of using.
WO2008115319A3 (en) Conjugates of synthetic tlr agonists and uses therefor
WO2008106228A3 (en) Methods and compositions for normalizing meibomian gland secretions
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2007021672A3 (en) Vaccination against dengue virus infection
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
WO2005112546A3 (en) Mucinous glycoprotein (muc-1) vaccine
WO2008045346A3 (en) Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use
WO2006091722A3 (en) Alkyl-glycoside enhanced vaccination
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2007106915A3 (en) Antibodies to egfl7 and methods for their use
WO2006105234A3 (en) Hybrid inorganic nanoparticles, methods of using and methods of making
WO2007028151A3 (en) Surgical devices and related methods thereof
WO2006050826A3 (en) Treatment of mastitis with enrofloxacin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase